(Updates with the stock move in the headline and the first paragraph.)
Soleno Therapeutics (SLNO) shares jumped 37% in premarket activity Thursday after the company said overnight that the US Food and Drug Administration approved its treatment for hyperphagia in adults and children with Prader-Willi Syndrome, a rare genetic disorder.
The approval for the company's VYKAT XR tablets was based on efficacy and safety data from a phase 3 trial, it said late Wednesday.
Soleno expects the tablets to be available in the US in April.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。